Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H30NO3.Br |
Molecular Weight | 448.393 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].CC(C)[N+](C)(CCOC(=O)C1C2=C(OC3=C1C=CC=C3)C=CC=C2)C(C)C
InChI
InChIKey=XLBIBBZXLMYSFF-UHFFFAOYSA-M
InChI=1S/C23H30NO3.BrH/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22;/h6-13,16-17,22H,14-15H2,1-5H3;1H/q+1;/p-1
DescriptionSources: https://www.drugs.com/pro/propantheline.htmlCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00782 | http://reference.medscape.com/drug/pro-banthine-propantheline-342000 | https://www.ncbi.nlm.nih.gov/pubmed/12049493
Sources: https://www.drugs.com/pro/propantheline.html
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00782 | http://reference.medscape.com/drug/pro-banthine-propantheline-342000 | https://www.ncbi.nlm.nih.gov/pubmed/12049493
Propantheline is an antimuscarinic agent used for the treatment of excessive sweating (hyperhidrosis), cramps or spasms of the stomach, intestines (gut) or bladder, and involuntary urination (enuresis). It can also be used to control the symptoms of irritable bowel syndrome and similar conditions. Propantheline is one of a group of antispasmodic medications which work by blocking the action of the chemical messenger acetylcholine, which is produced by nerve cells, to muscarinic receptors present in various smooth muscular tissues, in places such as the gut, bladder, and eye. Normally, the binding of acetylcholine induces involuntary smooth muscular contractions. Varying degrees of drying of salivary secretions may occur as well as decreased sweating. Ophthalmic side effects include blurred vision, mydriasis, cycloplegia, and increased ocular tension. Other reported adverse reactions include urinary hesitancy and retention, tachycardia, palpitations, loss of the sense of taste, headache, nervousness, mental confusion, drowsiness, weakness, dizziness, insomnia, nausea, vomiting, constipation, bloated feeling, impotence, suppression of lactation, and allergic reactions or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
9.48 null [pKi] | ||
Target ID: CHEMBL216 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
9.66 null [pKi] | ||
Target ID: CHEMBL245 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
10.04 null [pKi] | ||
Target ID: CHEMBL1821 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493 |
10.24 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PRO-BANTHINE Approved UsePropantheline bromide is effective as adjunctive therapy in the treatment of peptic ulcer. Launch Date1953 |
|||
Primary | PRO-BANTHINE Approved UsePropantheline bromide is effective as adjunctive therapy in the treatment of peptic ulcer. Launch Date1953 |
|||
Primary | PRO-BANTHINE Approved UsePropantheline bromide is effective as adjunctive therapy in the treatment of peptic ulcer. Launch Date1953 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
51.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6689152 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
53.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
20.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
186.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6689152 |
45 mg single, oral dose: 45 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
159 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
62.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.56 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7389749 |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
PROPANTHELINE BROMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo. | 2001 Jul |
|
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. | 2002 |
|
Clinical pharmacokinetics of drugs used to treat urge incontinence. | 2003 |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2003 |
|
Interleukin-1 (IL-1) system gene expression in granulosa cells: kinetics during terminal preovulatory follicle maturation in the mare. | 2003 May 16 |
|
Cumulus expansion, nuclear maturation and connexin 43, cyclooxygenase-2 and FSH receptor mRNA expression in equine cumulus-oocyte complexes cultured in vitro in the presence of FSH and precursors for hyaluronic acid synthesis. | 2004 Jun 22 |
|
Propantheline and in vitro reactivity of urinary bladder smooth muscle in guinea pigs. | 2005 |
|
Ocular complications of neurological therapy. | 2005 Jul |
|
Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. | 2005 Jun |
|
In vivo effect of interleukin-1beta and interleukin-1RA on oocyte cytoplasmic maturation, ovulation, and early embryonic development in the mare. | 2005 Jun 22 |
|
Evaluation of antimotility effect of Lantana camara L. var. acuelata constituents on neostigmine induced gastrointestinal transit in mice. | 2005 Sep 17 |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2006 Apr 19 |
|
Masking mechanisms of bitter taste of drugs studied with ion selective electrodes. | 2006 Aug |
|
Prophylaxis of mucosal toxicity by oral propantheline and cryotherapy in children with malignancies undergoing myeloablative chemo-radiotherapy. | 2006 Dec |
|
Interventions for preventing oral mucositis for patients with cancer receiving treatment. | 2007 Oct 17 |
|
The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury. | 2007 Oct 22 |
|
No effect of imidafenacin, a novel antimuscarinic drug, on digoxin pharmacokinetics in healthy subjects. | 2008 |
|
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. | 2008 Apr |
|
Methyl 9H-xanthene-9-carboxyl-ate. | 2008 Apr 16 |
|
Suspected differential interactions of digoxin with imidafenacin and propantheline; some thoughts for introspection. | 2009 |
|
Anticholinergics for urinary symptoms in multiple sclerosis. | 2009 Jan 21 |
|
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/propantheline.html
The usual initial adult dose of Propantheline bromide tablets is 15 mg taken 30 minutes before each meal and 30 mg at bedtime (a total of 75 mg daily). Subsequent dosage adjustment should be made according to the patient’s individual response and tolerance.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12049493
Binding studies were performed with [3 H]NMS following the protocol from RBI. The binding buffer, pH 7.4, consisted of 0.15 M NaCl, 1.5 mM KH2 PO4 , and 2.7 mM Na2 HPO4 . NaF 10 mM was added to the buffer as an esterase inhibitor. The assay mixture (1 mL) contained 100 μL diluted membranes (receptor proteins, final concentration: m1 25 μg/mL, m2 42 μg/mL, m3 15.9 μg/mL, m4 20 μg/mL). Final concentrations of [3 H]NMS for the m2-m4 binding studies were 0.5 nM and 1 nM for m1. Specific binding was defined as the difference between the [3 H]NMS binding in the absence and presence of 1 μM atropine. Incubation was carried out at room temperature for 60 minutes. The assay was terminated by filtration through a Whatman GF/B filter (presoaked with 0.5% polyethyleneimine). The filter was then washed 3 times with 10 mL ice-cold binding buffer, transferred to vials, and added with 10 mL of Scintiverse liquid. Finally, detection was performed on a Packard 31800 liquid scintillation analyzer
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C29383
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
100000081151
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
SUB10098MIG
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
UX9Z118X9F
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
m9189
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
UX9Z118X9F
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
226
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
8762
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1180725
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
757294
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
9279
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
200-030-6
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
DBSALT000225
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
DTXSID2023519
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
1570508
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
PROPANTHELINE BROMIDE
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY | |||
|
50-34-0
Created by
admin on Fri Dec 15 15:13:24 GMT 2023 , Edited by admin on Fri Dec 15 15:13:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD